Summary of the technology
A method for the treatment of hepatic encephalopathy comprising administering to a subject in need of such treatment an effective amount of D9-tetrahydrocannabinol (THC) or Cannabidiol.
keywords: hepatic, encephalopathy
Originally: 12-2007-1885, 12-2007-1878 12-2006-577- 3 projects combined into one
Project ID : 12-2006-577
Description of the technology
Prof. Yaron Ilan, Department of Human Nutrition and Metabolism and Liver Unit Hadassah Hospital
Cannabinoids/endocannabinoids and/or capsaicin or cannabidiol, improve both liver and brain functions
Nutrition and Metabolism, Treatment, Hepatic Encephalopathy, Liver Cirrhosis, Liver Steatosis.
Proved mice model experiments
PCT application- WO 2008/050344 A2
1.87/1000 patients. in hospital admission.
To date, there is no effective treatment of liver diseases with the related
- Hepatic-Encephalopathy occurs in:
- 30-45% of patients with cirrhosis.
- 10-50% of patients with transjugular intrahepatic portosystemic shunt.
- Minimal symptoms of Hepatic-Encephalopathy occur in 20-60% of patients with liver diseases.
- 30% of patients dying of end stage liver diseases experience significant Hepatic-Encephalopathy.
- NAFLD is estimated to occur in one-third of the general population in the US.
- Strategies to lower ammonia production/absorption.
- Medications to counteract ammonia effect on brain cell function.
- Devices to compensate liver dysfunction.
- Liver transplantation.
- Treatment of liver disease(Cirrhosis/steatosis) and hepatic encephalopathy with cannabidiol or capsaicin and/or cannabinoids (THC/HU308) / endocannabinoids ( 2-AG).
- Method of administration: oral, parenteral, sublingual or intranasal is yet to be determined.
- Has been shown to improve both liver and brain function in a mouse models of hepatic encephalopathy(Both acute and chronic models).
- No side effects were noticed (FHF acute model)(BDL chronic model).
- No toxicity in chronic administration.
We have shown in mouse experimental models that cannabinoids/endocannabinoids and/or capsaicin or cannabidiol, improve both liver and brain functions. We suggest a treatment modality based on the following mechanism/s: blocking the CB1 receptor and stimulating the CB2 receptor by 2AG or HU308 or THC (for hepatic encephalopathy) and/or the TRPV1 receptors by capsaicin and/or the 5HTIA receptors by Cannabidiol . Thus, inducing therapeutic effect which is mediated through effects in the liver and brain.
The Business Opportunity
We are presently seeking to raise 0.5M.US$ to complete efficacy and safety studies in animal models and to Progress to preliminary human studies (safety and proof of concept) once pre-clinical safety has been determined .
Researcher’s information: http://www.hadassah.org.il/atarim/medicine/d5.htm